Skip to main content
Erschienen in: European Archives of Oto-Rhino-Laryngology 8/2011

01.08.2011 | Miscellaneous

Bisphosphonate-induced osteonecrosis of the external ear canal: a retrospective study

verfasst von: K. Froelich, A. Radeloff, C. Köhler, R. Mlynski, J. Müller, R. Hagen, N. H. Kleinsasser

Erschienen in: European Archives of Oto-Rhino-Laryngology | Ausgabe 8/2011

Einloggen, um Zugang zu erhalten

Abstract

In 2003, osteonecrosis of the jaw was described as an intraoral complication of bisphosphonate therapy. More recently, cases of avascular necrosis of the hip were reported in patients with long-lasting bisphosphonate therapy. Thus, it was the aim of the present study to analyze cases of benign osteonecrosis of the external ear canal and to retrospectively identify a possible relationship to long-lasting bisphosphonate therapy. 13 patients with osteonecrosis of the external ear canal operated on between 2005 and 2009 were included. Patient histories were reviewed for possible previous or current bisphosphonate therapy. Three patients with osteonecrosis of the external ear canal and long-term bisphosphonate therapy could be identified. They had been treated either for breast cancer or multiple myeloma. Certainly, the jaw is an area of increased risk for developing osteonecrosis with its high mechanical stress and intraoral bacterial flora. However, osteonecrosis of the hips and the external ear canal in patients receiving long-term bisphosphonate therapy necessitate further investigation of a possible systemic, bisphosphonate-related phenomenon.
Literatur
1.
Zurück zum Zitat Steiner B, Lenz JH, Gundlach KK, Freund M (2005) Osteonecrosis of the jaws during treatment with bisphosphonates: diagnosis and therapy. Dtsch Med Wochenschr 130:2142–2145PubMedCrossRef Steiner B, Lenz JH, Gundlach KK, Freund M (2005) Osteonecrosis of the jaws during treatment with bisphosphonates: diagnosis and therapy. Dtsch Med Wochenschr 130:2142–2145PubMedCrossRef
2.
Zurück zum Zitat Fleisch H, Russell RG, Bisaz S, Casey PA, Mühlbauer RC (1968) The influence of pyrophosphate analogues (diphosphonates) on the precipitation and dissolution. Calcif Tissue Res Suppl: 10–10a Fleisch H, Russell RG, Bisaz S, Casey PA, Mühlbauer RC (1968) The influence of pyrophosphate analogues (diphosphonates) on the precipitation and dissolution. Calcif Tissue Res Suppl: 10–10a
3.
Zurück zum Zitat Fleisch H (1998) Bisphosphonates: mechanisms of action. Endocrine Rev 19:80–100CrossRef Fleisch H (1998) Bisphosphonates: mechanisms of action. Endocrine Rev 19:80–100CrossRef
5.
Zurück zum Zitat Fleisch H, Russell RG, Francis MD (1969) Diphosphonates inhibit hydroxyapatite dissolution in vitro and bone resorption in tissue culture and in vivo. Science 165:1262–1264PubMedCrossRef Fleisch H, Russell RG, Francis MD (1969) Diphosphonates inhibit hydroxyapatite dissolution in vitro and bone resorption in tissue culture and in vivo. Science 165:1262–1264PubMedCrossRef
6.
Zurück zum Zitat Francis MD, Russell RG, Fleisch H (1969) Diphosphonates inhibit formation of calcium phosphate crystals in vitro and pathological calcification in vivo. Science 165:1264–1266PubMedCrossRef Francis MD, Russell RG, Fleisch H (1969) Diphosphonates inhibit formation of calcium phosphate crystals in vitro and pathological calcification in vivo. Science 165:1264–1266PubMedCrossRef
7.
Zurück zum Zitat Sarin J, DeRossi SS, Akintoye SO (2008) Updates on bisphosphonates and potential pathobiology of bisphosphonate-induced jaw osteonecrosis. Oral Dis 14:277–285PubMedCrossRef Sarin J, DeRossi SS, Akintoye SO (2008) Updates on bisphosphonates and potential pathobiology of bisphosphonate-induced jaw osteonecrosis. Oral Dis 14:277–285PubMedCrossRef
8.
Zurück zum Zitat Suleman YF, Meer S, Lurie R (2007) Bisphosphonate-induced osteonecrosis of the jaws: review, clinical implications and case report. Head Neck Pathol 1:156–164PubMedCrossRef Suleman YF, Meer S, Lurie R (2007) Bisphosphonate-induced osteonecrosis of the jaws: review, clinical implications and case report. Head Neck Pathol 1:156–164PubMedCrossRef
9.
Zurück zum Zitat Badros A, Weikel D, Salama A et al (1996) Osteonecrosis of the jaw in multiple myeloma patients: clinical features and risk factors. J Clin Oncol 24:945–952CrossRef Badros A, Weikel D, Salama A et al (1996) Osteonecrosis of the jaw in multiple myeloma patients: clinical features and risk factors. J Clin Oncol 24:945–952CrossRef
10.
Zurück zum Zitat Walter C, Al-Nawas B, du Bois A, Buch L, Harter P, Grötz KA (2009) Incidence of bisphosphonate-associated osteonecrosis of the jaws in breast cancer patients. Cancer 115:1631–1637PubMedCrossRef Walter C, Al-Nawas B, du Bois A, Buch L, Harter P, Grötz KA (2009) Incidence of bisphosphonate-associated osteonecrosis of the jaws in breast cancer patients. Cancer 115:1631–1637PubMedCrossRef
11.
Zurück zum Zitat Abe Y, Kawakami A, Nakashima T et al (2000) Etidronate inhibits human osteoblast apoptosis by inhibition of pro-apoptotic factor(s) produced by activated T cells. J Lab Clin Med 136:344–354PubMedCrossRef Abe Y, Kawakami A, Nakashima T et al (2000) Etidronate inhibits human osteoblast apoptosis by inhibition of pro-apoptotic factor(s) produced by activated T cells. J Lab Clin Med 136:344–354PubMedCrossRef
12.
Zurück zum Zitat Itoh F, Aoyagi S, Furihata-Komatsu H et al (2003) Clodronate stimulates osteoblast differentiation in ST2 and MC3T3-E1 cells and rat organ cultures. Eur J Pharmacol 477:9–16PubMedCrossRef Itoh F, Aoyagi S, Furihata-Komatsu H et al (2003) Clodronate stimulates osteoblast differentiation in ST2 and MC3T3-E1 cells and rat organ cultures. Eur J Pharmacol 477:9–16PubMedCrossRef
13.
Zurück zum Zitat Green JR, Clézardin P (2002) Mechanisms of bisphosphonate effects on osteoclasts, tumor cell growth, and metastasis. Am J Clin Oncol 25(6 Suppl1):S3–S9PubMedCrossRef Green JR, Clézardin P (2002) Mechanisms of bisphosphonate effects on osteoclasts, tumor cell growth, and metastasis. Am J Clin Oncol 25(6 Suppl1):S3–S9PubMedCrossRef
14.
Zurück zum Zitat Woo SB, Hellstein JW, Kalmar JR (2006) Narrative review: bisphosphonates and osteonecrosis of the jaws. Ann Intern Med 144:753–761PubMed Woo SB, Hellstein JW, Kalmar JR (2006) Narrative review: bisphosphonates and osteonecrosis of the jaws. Ann Intern Med 144:753–761PubMed
15.
Zurück zum Zitat Marx RE (2003) Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaws: a growing epidemic. J Oral Maxillofac Surg 61:1115–1117PubMedCrossRef Marx RE (2003) Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaws: a growing epidemic. J Oral Maxillofac Surg 61:1115–1117PubMedCrossRef
16.
Zurück zum Zitat Marx RE, Sawatari Y, Fortin M, Broumand V (2005) Bisphosphonate-induced exposed bone (osteonecrosis/osteopetrosis) of the jaws: risk factors, recognition, prevention, and treatment. J Oral Maxillofac Surg 63:1567–1575PubMedCrossRef Marx RE, Sawatari Y, Fortin M, Broumand V (2005) Bisphosphonate-induced exposed bone (osteonecrosis/osteopetrosis) of the jaws: risk factors, recognition, prevention, and treatment. J Oral Maxillofac Surg 63:1567–1575PubMedCrossRef
17.
Zurück zum Zitat Boonyapakorn T, Schirmer I, Reichart PA, Sturm I, Massenkeil G (2008) Bisphosphonate-induced osteonecrosis of the jaws: prospective study of 80 patients with multiple myeloma and other malignancies. Oral Oncol 44:857–869PubMedCrossRef Boonyapakorn T, Schirmer I, Reichart PA, Sturm I, Massenkeil G (2008) Bisphosphonate-induced osteonecrosis of the jaws: prospective study of 80 patients with multiple myeloma and other malignancies. Oral Oncol 44:857–869PubMedCrossRef
18.
Zurück zum Zitat Hoff AO, Toth BB, Altundag K et al (2008) Frequency and risk factors associated with osteonecrosis of the jaw in cancer patients treated with intravenous bisphosphonates. J Bone Miner Res 23:826–836PubMedCrossRef Hoff AO, Toth BB, Altundag K et al (2008) Frequency and risk factors associated with osteonecrosis of the jaw in cancer patients treated with intravenous bisphosphonates. J Bone Miner Res 23:826–836PubMedCrossRef
19.
Zurück zum Zitat Fehm T, Beck V, Banys M, Lipp HP et al (2009) Bisphosphonate-induced osteonecrosis of the jaw (ONJ): incidence and risk factors in patients with breast cancer and gynecological malignancies. Gynecol Oncol 112:605–609PubMedCrossRef Fehm T, Beck V, Banys M, Lipp HP et al (2009) Bisphosphonate-induced osteonecrosis of the jaw (ONJ): incidence and risk factors in patients with breast cancer and gynecological malignancies. Gynecol Oncol 112:605–609PubMedCrossRef
20.
Zurück zum Zitat Kumar BN, Walsh RM, Sinha A, Courteney-Harris RG, Carlin WV (1997) Benign necrotizing osteitis of the external auditory meatus. J Laryngol Otol 111:269–270PubMed Kumar BN, Walsh RM, Sinha A, Courteney-Harris RG, Carlin WV (1997) Benign necrotizing osteitis of the external auditory meatus. J Laryngol Otol 111:269–270PubMed
21.
Zurück zum Zitat Tsikoudas A, Davis BC (2009) Benign necrotizing otitis externa. Ear Nose Throat J 88:E18PubMed Tsikoudas A, Davis BC (2009) Benign necrotizing otitis externa. Ear Nose Throat J 88:E18PubMed
22.
Zurück zum Zitat Wolf M, Nusem-Horowitz S, Zwas ST, Horowitz A, Kronenberg J (1997) Benign osteonecrosis of the external ear canal. Laryngoscope 107:478–482PubMedCrossRef Wolf M, Nusem-Horowitz S, Zwas ST, Horowitz A, Kronenberg J (1997) Benign osteonecrosis of the external ear canal. Laryngoscope 107:478–482PubMedCrossRef
23.
Zurück zum Zitat Youngs R, Kwok P, Hawke M (1988) Benign osteitis of the external auditory meatus. J Otolaryngol 17:302–307PubMed Youngs R, Kwok P, Hawke M (1988) Benign osteitis of the external auditory meatus. J Otolaryngol 17:302–307PubMed
24.
Zurück zum Zitat Durie BG, Salmon SE (1975) A clinical staging system for multiple myeloma. Correlation of measured myeloma cell mass with presenting clinical features, response to treatment, and survival. Cancer 36:842–854PubMedCrossRef Durie BG, Salmon SE (1975) A clinical staging system for multiple myeloma. Correlation of measured myeloma cell mass with presenting clinical features, response to treatment, and survival. Cancer 36:842–854PubMedCrossRef
25.
Zurück zum Zitat Bassett CA, Donath A, Macagno F, Preisig R, Fleisch H, Francis MD (1969) Diphosphonates in the treatment of myositis ossificans. Lancet 2:845PubMedCrossRef Bassett CA, Donath A, Macagno F, Preisig R, Fleisch H, Francis MD (1969) Diphosphonates in the treatment of myositis ossificans. Lancet 2:845PubMedCrossRef
26.
Zurück zum Zitat Jowsey J, Riggs BL, Kelly PJ, Hoffman DL, Bordier P (1971) The treatment of osteoporosis with disodium ethane-1, 1-diphosphonate. J Lab Clin Med 78:574–584PubMed Jowsey J, Riggs BL, Kelly PJ, Hoffman DL, Bordier P (1971) The treatment of osteoporosis with disodium ethane-1, 1-diphosphonate. J Lab Clin Med 78:574–584PubMed
27.
Zurück zum Zitat Russell RG, Smith R (1973) Diphosphonates. Experimental and clinical aspects. J Bone Joint Surg Br 55:66–86PubMed Russell RG, Smith R (1973) Diphosphonates. Experimental and clinical aspects. J Bone Joint Surg Br 55:66–86PubMed
28.
Zurück zum Zitat Smith R, Russell RG, Bishop M (1971) Diphosphonates and Paget’s disease of bone. Lancet 1:945–947PubMedCrossRef Smith R, Russell RG, Bishop M (1971) Diphosphonates and Paget’s disease of bone. Lancet 1:945–947PubMedCrossRef
29.
Zurück zum Zitat Khan AA, Sándor GK, Dore E (2009) Canadian Taskforce on osteonecrosis of the Jaw: bisphosphonate associated osteonecrosis of the jaw. J Rheumatol 36:478–490PubMedCrossRef Khan AA, Sándor GK, Dore E (2009) Canadian Taskforce on osteonecrosis of the Jaw: bisphosphonate associated osteonecrosis of the jaw. J Rheumatol 36:478–490PubMedCrossRef
30.
Zurück zum Zitat Sarasquete ME, González M, San Miguel JF, García-Sanz R (2009) Bisphosphonate-related osteonecrosis: genetic and acquired risk factors. Oral Dis 15:382–387PubMedCrossRef Sarasquete ME, González M, San Miguel JF, García-Sanz R (2009) Bisphosphonate-related osteonecrosis: genetic and acquired risk factors. Oral Dis 15:382–387PubMedCrossRef
31.
Zurück zum Zitat Diel IJ, Bergner R, Grötz KA (2007) Adverse effects of bisphosphonates: current issues. J Support Oncol 5:475–482PubMed Diel IJ, Bergner R, Grötz KA (2007) Adverse effects of bisphosphonates: current issues. J Support Oncol 5:475–482PubMed
32.
Zurück zum Zitat Migliorati CA, Schubert MM, Peterson DE, Seneda LM (2005) Bisphosphonate-associated osteonecrosis of mandibular and maxillary bone: an emerging oral complication of supportive cancer therapy. Cancer 104:83–93PubMedCrossRef Migliorati CA, Schubert MM, Peterson DE, Seneda LM (2005) Bisphosphonate-associated osteonecrosis of mandibular and maxillary bone: an emerging oral complication of supportive cancer therapy. Cancer 104:83–93PubMedCrossRef
33.
Zurück zum Zitat Walter C, Klein MO, Pabst A, Al-Nawas B, Duschner H, Ziebart T (2010) Influence of bisphosphonates on endothelial cells, fibroblasts, and osteogenic cells. Clin Oral Investig 14:35–41PubMedCrossRef Walter C, Klein MO, Pabst A, Al-Nawas B, Duschner H, Ziebart T (2010) Influence of bisphosphonates on endothelial cells, fibroblasts, and osteogenic cells. Clin Oral Investig 14:35–41PubMedCrossRef
34.
Zurück zum Zitat Aguiar Bujanda D, Bohn Sarmiento U, Cabrera Suárez MA, Aguiar Morales J (2007) Assessment of renal toxicity and osteonecrosis of the jaws in patients receiving zoledronic acid for bone metastasis. Ann Oncol 18:556–560PubMedCrossRef Aguiar Bujanda D, Bohn Sarmiento U, Cabrera Suárez MA, Aguiar Morales J (2007) Assessment of renal toxicity and osteonecrosis of the jaws in patients receiving zoledronic acid for bone metastasis. Ann Oncol 18:556–560PubMedCrossRef
35.
Zurück zum Zitat Ruggiero SL, Dodson TB, Assael LA, Landesberg R, Marx RE, Mehrotra B, for the Task Force on Bisphosphonate-Related Osteonecrosis of the Jaws, American Association of Oral, Maxillofacial Surgeons (2009) American Association of Oral and Maxillofacial Surgeons position paper on bisphosphonate-related osteonecrosis of the jaw—2009 update. Aust Endod J 35:119–130PubMedCrossRef Ruggiero SL, Dodson TB, Assael LA, Landesberg R, Marx RE, Mehrotra B, for the Task Force on Bisphosphonate-Related Osteonecrosis of the Jaws, American Association of Oral, Maxillofacial Surgeons (2009) American Association of Oral and Maxillofacial Surgeons position paper on bisphosphonate-related osteonecrosis of the jaw—2009 update. Aust Endod J 35:119–130PubMedCrossRef
36.
Zurück zum Zitat Pazianas M, Miller P, Blumentals WA, Bernal M, Kothawala P (2007) A review of the literature on osteonecrosis of the jaw in patients with osteoporosis treated with oral bisphosphonates: prevalence, risk factors, and clinical characteristics. Clin Ther 29:1548–1558PubMedCrossRef Pazianas M, Miller P, Blumentals WA, Bernal M, Kothawala P (2007) A review of the literature on osteonecrosis of the jaw in patients with osteoporosis treated with oral bisphosphonates: prevalence, risk factors, and clinical characteristics. Clin Ther 29:1548–1558PubMedCrossRef
37.
Zurück zum Zitat Ziebart T, Pabst A, Klein MO, Kämmerer P, Gauss L, Brüllmann D, Al-Nawas B, Walter C et al. (2009) Bisphosphonates: restrictions for vasculogenesis and angiogenesis: inhibition of cell function of endothelial progenitor cells and mature endothelial cells in vitro. Clin Oral Investig [Epub ahead of print] Ziebart T, Pabst A, Klein MO, Kämmerer P, Gauss L, Brüllmann D, Al-Nawas B, Walter C et al. (2009) Bisphosphonates: restrictions for vasculogenesis and angiogenesis: inhibition of cell function of endothelial progenitor cells and mature endothelial cells in vitro. Clin Oral Investig [Epub ahead of print]
38.
Zurück zum Zitat Santini D, Vincenzi B, Avvisati G, Dicuonzo G et al (2002) Pamidronate induces modifications of circulating angiogenetic factors in cancer patients. Clin Cancer Res 8:1080–1084PubMed Santini D, Vincenzi B, Avvisati G, Dicuonzo G et al (2002) Pamidronate induces modifications of circulating angiogenetic factors in cancer patients. Clin Cancer Res 8:1080–1084PubMed
39.
Zurück zum Zitat Scheper MA, Badros A, Chaisuparat R, Cullen KJ, Meiller TF (2009) Effect of zoledronic acid on oral fibroblasts and epithelial cells: a potential mechanism of bisphosphonate-associated osteonecrosis. Br J Haematol 144:667–676PubMedCrossRef Scheper MA, Badros A, Chaisuparat R, Cullen KJ, Meiller TF (2009) Effect of zoledronic acid on oral fibroblasts and epithelial cells: a potential mechanism of bisphosphonate-associated osteonecrosis. Br J Haematol 144:667–676PubMedCrossRef
40.
Zurück zum Zitat Landesberg R, Cozin M, Cremers S et al (2008) Inhibition of oral mucosal cell wound healing by bisphosphonates. J Oral Maxillofac Surg 66:839–847PubMedCrossRef Landesberg R, Cozin M, Cremers S et al (2008) Inhibition of oral mucosal cell wound healing by bisphosphonates. J Oral Maxillofac Surg 66:839–847PubMedCrossRef
41.
Zurück zum Zitat Simon MJ, Niehoff P, Kimmig B, Wiltfang J, Açil Y (2010) Expression profile and synthesis of different collagen types I, II, III, and V of human gingival fibroblasts, osteoblasts, and SaOS-2 cells after bisphosphonate treatment. Clin Oral Investig 14:51–58PubMedCrossRef Simon MJ, Niehoff P, Kimmig B, Wiltfang J, Açil Y (2010) Expression profile and synthesis of different collagen types I, II, III, and V of human gingival fibroblasts, osteoblasts, and SaOS-2 cells after bisphosphonate treatment. Clin Oral Investig 14:51–58PubMedCrossRef
Metadaten
Titel
Bisphosphonate-induced osteonecrosis of the external ear canal: a retrospective study
verfasst von
K. Froelich
A. Radeloff
C. Köhler
R. Mlynski
J. Müller
R. Hagen
N. H. Kleinsasser
Publikationsdatum
01.08.2011
Verlag
Springer-Verlag
Erschienen in
European Archives of Oto-Rhino-Laryngology / Ausgabe 8/2011
Print ISSN: 0937-4477
Elektronische ISSN: 1434-4726
DOI
https://doi.org/10.1007/s00405-011-1496-z

Weitere Artikel der Ausgabe 8/2011

European Archives of Oto-Rhino-Laryngology 8/2011 Zur Ausgabe

Bei schweren Reaktionen auf Insektenstiche empfiehlt sich eine spezifische Immuntherapie

Insektenstiche sind bei Erwachsenen die häufigsten Auslöser einer Anaphylaxie. Einen wirksamen Schutz vor schweren anaphylaktischen Reaktionen bietet die allergenspezifische Immuntherapie. Jedoch kommt sie noch viel zu selten zum Einsatz.

HNO-Op. auch mit über 90?

16.04.2024 HNO-Chirurgie Nachrichten

Mit Blick auf das Risiko für Komplikationen nach elektiven Eingriffen im HNO-Bereich scheint das Alter der Patienten kein ausschlaggebender Faktor zu sein. Entscheidend ist offenbar, wie fit die Betroffenen tatsächlich sind.

Intrakapsuläre Tonsillektomie gewinnt an Boden

16.04.2024 Tonsillektomie Nachrichten

Gegenüber der vollständigen Entfernung der Gaumenmandeln hat die intrakapsuläre Tonsillektomie einige Vorteile, wie HNO-Fachleute aus den USA hervorheben. Sie haben die aktuelle Literatur zu dem Verfahren gesichtet.

Bilateraler Hörsturz hat eine schlechte Prognose

15.04.2024 Hörsturz Nachrichten

Die Mehrzahl der Menschen mit Hörsturz ist einseitig betroffen, doch auch ein beidseitiger Hörsturz ist möglich. Wie häufig solche Fälle sind und wie sich ihr Verlauf darstellt, hat eine HNO-Expertenrunde aus den USA untersucht.

Update HNO

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert – ganz bequem per eMail.